Ocugen Signs MENA Licensing Deal for OCU400

MT newswire2026/10/14 11:13

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

07:13 AM EDT, 10/14/2026 (MT Newswires) -- Ocugen (OCGN) said Wednesday that it signed a licensing agreement with Roots Pharmaceutical and Al-Dhow International for exclusive Middle East and North Africa rights to its OCU400 gene therapy for retinitis pigmentosa. Ocugen said it could receive up to $4 million in development milestones, $255 million in sales milestones and 22% royalties on net sales. The company said it will manufacture commercial supplies. Phase 3 trial results are expected in Q1 2027, ahead of planned global regulatory submissions, it added.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.

华尔街见闻•2026/11/08 12:41